Nitescu P, Hultman E, Appelgren L, Linder L E, Curelaru I
Department of Anaesthesiology, Sahlgrenska Hospital, Gothenburg, Sweden.
Clin J Pain. 1992 Dec;8(4):324-37. doi: 10.1097/00002508-199212000-00007.
To provide a basis for recommendations on the exchange of containers (syringes and cassettes) and antibacterial filters, and for choice of administration device in patients with "refractory" pain treated with long-term percutaneous intrathecal (IT) infusions of opioid (morphine or buprenorphine) and bupivacaine mixtures.
Prospective, cohort, nonrandomized control trial-case series, with consecutive sample, no standard criterion, and cost-benefit analysis.
Tertiary care center, institutional practice as well as hospitalized and ambulatory care.
Eighty-nine (51 women and 38 men); 81 with malignant pain and 8 with benign "refractory" pain.
(a) The chemical stability of the drugs in the containers during 30 days. (b) The results of bacteriologic culture of the residual volumes of the analgesic mixtures from used and reused (1-16 times) syringes (n = 135) and cassettes (n = 258), and of 5 ml of sterile isotonic saline filtered through the used Millipore filters (n = 149). The bacteriologic samples from the 89 patients were taken after 1-40 (median = 7), 1-86 (median = 20), and 5-78 (median = 31) days of IT treatment, respectively.
Chemical stability: buprenorphine and bupivacaine concentrations-liquid chromatography; morphine concentrations--gas chromatography. Bacteriologic cultures: standard laboratory procedures. The hypothesis (repeated use of the infusion systems and their exchange once a month does not significantly affect drug concentrations or increase the infection risk) was elaborated before data collection began.
The bupivacaine-opioid mixtures were found to be chemically stable within 3-10% of the original doses up to 30 days. Seventeen cultures (from five syringes, six cassettes, and six filters) in 13 patients (having no signs of meningeal infection) were found to be colonized with Staphylococcus aureus (n = 4), coagulase negative staphylococci (n = 7), viridans streptococci (n = 3), Neisseria sp (n = 4), Corynebacterium sp (n = 4), Enterobacter sp (n = 2), Klebsiella sp (n = 3), gram-negative bacilli (n = 1), and yeasts (n = 2). The place of IT treatment, its duration, and patient-related infection risk factors (age; malignancy; diabetes; presence of a colostomy, pyelostomy, or indwelling urinary catheter; and the presence and location of infection foci) were not related to the results of the cultures. However, 9 of the 17 positive cultures came from patients with skin ulcers, a notable incidence. The positive cultures had no connection with the cultured item, its in-use duration, the number of times of reuse, the analgesic drugs used, their concentrations or the presence of preservatives (sodium metabisulfite and sodium edetate), or the antiseptic agent (70% ethanol or 0.5% chlorhexidine gluconate) used during bacteriologic sampling. The bacterial growth was sparse in 14 and massive in 3 of the 17 positive cultures. One item (filter) from one patient with meningitis was sterile.
In our population, exchange of the infusion systems when they are empty (within 1 month) and of the antibacterial filters once a month does not appear to affect the concentrations of, or increase the infection risk from, the opioid-bupivacaine mixtures. The risk of bacterial contamination/colonization of the syringes from syringe drivers does not seem to be higher than that of cassettes from external portable pumps.
为关于容器(注射器和储药盒)及抗菌过滤器的更换建议提供依据,并为长期经皮鞘内(IT)输注阿片类药物(吗啡或丁丙诺啡)和布比卡因混合液治疗“难治性”疼痛患者的给药装置选择提供依据。
前瞻性队列非随机对照试验病例系列,采用连续样本,无标准标准,并进行成本效益分析。
三级医疗中心、机构实践以及住院和门诊护理。
89例(51例女性和38例男性);81例患有恶性疼痛,8例患有良性“难治性”疼痛。
(a)药物在容器中的化学稳定性,为期30天。(b)对使用过和重复使用(1 - 16次)的注射器(n = 135)和储药盒(n = 258)中的镇痛混合液残余量以及通过使用过的密理博过滤器过滤的5 ml无菌等渗盐水(n = 149)进行细菌培养的结果。来自89例患者的细菌学样本分别在IT治疗1 - 40天(中位数 = 7天)、1 - 86天(中位数 = 20天)和5 - 78天(中位数 = 31天)后采集。
化学稳定性:丁丙诺啡和布比卡因浓度 - 液相色谱法;吗啡浓度 - 气相色谱法。细菌培养:标准实验室程序。该假设(输液系统的重复使用及其每月更换一次不会显著影响药物浓度或增加感染风险)在数据收集开始前就已拟定。
发现布比卡因 - 阿片类药物混合液在30天内化学稳定性在原始剂量的3% - 10%范围内。在13例患者(无脑膜感染迹象)中,17份培养物(来自5个注射器、6个储药盒和6个过滤器)被发现被金黄色葡萄球菌(n = 4)、凝固酶阴性葡萄球菌(n = 7)、草绿色链球菌(n = 3)、奈瑟菌属(n = 4)、棒状杆菌属(n = 4)、肠杆菌属(n = 2)、克雷伯菌属(n = 3)、革兰氏阴性杆菌(n = 1)和酵母菌(n = 2)定植。IT治疗的地点、持续时间以及与患者相关的感染风险因素(年龄;恶性肿瘤;糖尿病;是否存在结肠造口术、肾盂造口术或留置导尿管;以及感染灶的存在和位置)与培养结果无关。然而,17份阳性培养物中有9份来自有皮肤溃疡的患者,这一发生率值得注意。阳性培养物与培养物品、其使用持续时间、重复使用次数、使用的镇痛药物、其浓度或防腐剂(焦亚硫酸钠和依地酸钠)的存在,或细菌学采样期间使用的防腐剂(70%乙醇或0.5%葡萄糖酸氯己定)均无关联。17份阳性培养物中14份细菌生长稀疏,3份生长大量。1例患有脑膜炎患者的1件物品(过滤器)无菌。
在我们的研究人群中,输液系统在排空时(1个月内)更换以及抗菌过滤器每月更换一次似乎不会影响阿片类 - 布比卡因混合液的浓度,也不会增加其感染风险。来自注射器驱动装置的注射器细菌污染/定植风险似乎并不高于外部便携式泵的储药盒。